Underperforming is only one word for this diabolical mess.Shareprice should be $1 yet management couldn't give a stuff about the shareholders.How do we get rid of them?
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress